Targeting De Novo Lipogenesis by Different Approaches Shows Promise in Nonalcoholic Steatohepatitis

Affiliations

Comment

Brian DeBosch. Gastroenterology. 2022 Nov.

. 2022 Nov;163(5):1472.

doi: 10.1053/j.gastro.2022.07.085. Epub 2022 Aug 10.

¹ Department of Pediatrics and Cell Biology & Physiology, Washington University School of Medicine, St Louis, Missouri.

No abstract available

Comment on

Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
Morrow MR, Batchuluun B, Wu J, Ahmadi E, Leroux JM, Mohammadi-Shemirani P, Desjardins EM, Wang Z, Tsakiridis EE, Lavoie DCT, Reihani A, Smith BK, Kwiecien JM, Lally JSV, Nero TL, Parker MW, Ask K, Scott JW, Jiang L, Paré G, Pinkosky SL, Steinberg GR. Morrow MR, et al. Cell Metab. 2022 Jun 7;34(6):919-936.e8. doi: 10.1016/j.cmet.2022.05.004. Cell Metab. 2022. PMID: 35675800
MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH.
Gao H, Jin Z, Bandyopadhyay G, Cunha E Rocha K, Liu X, Zhao H, Zhang D, Jouihan H, Pourshahian S, Kisseleva T, Brenner DA, Ying W, Olefsky JM. Gao H, et al. Cell Metab. 2022 Jul 5;34(7):978-990.e4. doi: 10.1016/j.cmet.2022.05.008. Epub 2022 Jun 13. Cell Metab. 2022. PMID: 35700738 Free PMC article.